Dates that could move the NIB share price in 2024

NIB shares investors, get out your 2024 diaries…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The NIB Holdings Limited (ASX: NHF) share price is up 4.52% today to $7.98 amid many brokers tipping further growth in 2024.

As my Fool colleague Mitch points out, private insurance businesses have surged since the pandemic.

New data from APRA shows 11.81 million Australians have hospital coverage compared to 11.23 million in December 2019.

It seems that many Australians have decided health insurance is worth it amid long waiting lists for elective surgeries and specialist appointments and reduced Medicare bulk billing.

In FY23, NIB lifted its revenue by 10.9% to $3.1 billion and increased its net profit by 42.8% to $191 million. 

a woman puts a pen to her mouth as she smiles slightly while checking an old book style diary/calendar.

Image source: Getty Images

What are the brokers saying about the NIB share price?

Top broker Goldman Sachs reckons NIB is a buy and has a 12-month price target of $8.40.

The broker explains:

We are Buy-rated on NHF given: 1) it offers defensive exposure to the private health insurance sector which is experiencing favourable operating trends, 2) claims environment remains low with no immediate indications of a bounce back in claims, 3) DCL provisions to cover a bounce back in claims are proving redundant, 4) significant policyholder give back incentives suggest claiming environment remains well below expectations, 5) strong recovery in non-resident volume post Covid-19 through the return of international students, workers and visitor arrivals.

Citi also just upgraded NIB shares to a buy rating with an $8.35 share price target.

The important dates of 2024 for NIB investors

ASX shares tend to move on the days when important news is announced.

Helpfully, NIB today released its financial calender for 2024.

Here are the important dates in 2024 for NIB investors to note:

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has positions in and has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

ASX 300 healthcare stock outperforming today on 'strategic' leadership news

The ASX healthcare stock announced the outcome of its CEO recruitment drive this morning.

Read more »

Cropped shot of a young female scientist working on her computer in the laboratory.
Healthcare Shares

Could Telix shares be a millionaire-maker stock?

Telix looks a compelling growth story, with brokers eyeing more than 150% upside.

Read more »

A child covering his eyes hiding from a toy bear.
Healthcare Shares

Down 20% in 2026, is now the time to buy CSL shares?

CSL shares hit a new multi-year low as the 2026 decline deepens.

Read more »

Scientists in white coats look disappointed.
Healthcare Shares

Down 87% since Thursday, why is this ASX 300 healthcare stock sliding again today?

The ASX healthcare share has plunged more than 87% in five trading days.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Which ASX biotech's shares have jumped more than 10% on positive clinical trial news?

A potential cancer treatment is progressing.

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

3 ASX healthcare stocks tipped to soar over 100% higher this year

These ASX shares are on my radar this week.

Read more »

Scientists working in the laboratory and examining results.
Opinions

3 reasons to buy CSL shares today

The ASX biotech company has great growth potential this year.

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »